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SUMMARY
Twenty years of sky-high tuberculosis (TB) incidence rates and high TB mortality in high human
immunodeficiency virus (HIV) prevalence countries have so far not been matched by the same
magnitude or breadth of responses as seen in malaria or HIV programmes. Instead,
recommendations have been narrowly focused on people presenting to health facilities for
investigation of TB symptoms, or for HIV testing and care. However, despite the recent major
investment and scale-up of TB and HIV services, undiagnosed TB remains highly prevalent at
community level, implying that diagnosis of TB remains slow and incomplete. This maintains
high transmission rates and exposes people living with HIV to high rates of morbidity and
mortality.
More intensive use of TB screening, with broader definitions of target populations, expanded
indications for screening both inside and outside of health facilities, and appropriate selection of
new diagnostic tools, offers the prospect of rapidly improving population-level control of TB.
Diagnostic accuracy of suitable (high throughput) algorithms remains the major barrier to realising
this goal.
In the present study, we review the evidence available to guide expanded TB screening in HIV-
prevalent settings, ideally through combined TB-HIV interventions that provide screening for both
TB and HIV, and maximise entry to HIV and TB care and prevention. Ideally, we would
systematically test, treat and prevent TB and HIV comprehensively, offering both TB and HIV
screening to all health facility attendees, TB households and all adults in the highest risk
communities. However, we are still held back by inadequate diagnostics, financing and paucity of
population-impact data. Relevant contemporary research showing the high need for potential
gains, and pitfalls from expanded and intensified TB screening in high HIV prevalence settings are
discussed in this review.
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In high human immunodeficiency virus (HIV) prevalence settings, population-level
tuberculosis (TB) incidence increased in parallel with adult HIV prevalence in the 1990s and
remains extremely high, with over 1% of adults diagnosed with TB each year in many
Southern African towns.1 Outbreaks of multi- and extensively drug-resistant TB (XDR-TB)
have been generated in HIV care clinics, and then spread into general communities.2,3
Autopsy studies show that TB is the single biggest killer of people living with HIV
(PLHIV), being the cause in 32% to 45% of HIV-related deaths4 and with a high proportion
of fatal cases undiagnosed in life.4,5 Of the estimated 430 000 TB-related deaths among
PLHIV during 2011, 79% were in Africa. These stark facts demonstrate the urgent need to
strengthen TB prevention and care services using all available approaches, including more
ambitious TB screening strategies.
TB screening is the first step in both anti-tuberculosis treatment and TB prevention
pathways, and has an integral place in routine HIV care and infection control. Key potential
entry points for TB screening are illustrated in Figure 1. TB screening can be conducted at
the clinic, facility or community level (Table 1),6–12 and can be initiated by TB
programmes, infection control services in general facilities or HIV testing and care services.
Developing and scaling up effective TB screening strategies will ideally follow the same
kind of combined approach that has proved effective for HIV testing and counselling (HTC).
Diagnostic testing, provider-initiated HTC and promotion of client-initiated testing through
‘know your status’ campaigns in facility- and community-based testing services have led to
remarkable progress in universal access to HIV testing and care, with both HIV and TB
incidence rates falling regionally.13 Early HIV detection and antiretroviral therapy (ART)
are increasingly being recognised as critical for HIV prevention. Recommendations in the
United States are moving towards annual HIV screening for all adults, while in Africa
increasing emphasis is placed on home-based testing, due to much higher acceptability and
uptake than other modalities.14
These ambitious targets and achievements contrast with a more conservative approach to TB
screening. Although TB, like HIV, has characteristically prolonged infectiousness before
diagnosis that plays a critical role in maintaining transmission in the community, there is no
TB equivalent of the rapid diagnostic tests for HIV that provides highly sensitive and
specific results within 20 minutes and cost less than US$1. New diagnostics for TB,
increasing levels of political commitment to reducing HIV-related TB morbidity and
mortality, and the optimism arising from the success of ART scale-up has heightened
interest in TB screening, including ‘active’ and ‘intensified’ case-finding approaches in
communities.
SCREENING FOR TB AS PART OF THE RESPONSE TO TB-HIV IN HIGH HIV
PREVALENCE SETTINGS
International policy
International policy is supporting more intensive use of TB screening, with updated
recommendations for screening in PLHIV and close contacts of TB patients published by the
World Health Organization (WHO) in 2012 and guidance encouraging broader
consideration of screening in other priority groups, as well as operational research
priorities.15–17 More definitive TB screening guidelines will be published in 2013 following
systematic reviews that have highlighted major evidence gaps but which also stress the need
for caution.
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Rationale and general principles
The main aims of TB screening are 1) to reduce individual morbidity and mortality through
early diagnosis and treatment, 2) to reduce TB transmission by shortening the infectious
period (Figure 2) and 3) to exclude TB to allow preventive treatment (such as isoniazid) to
be started. In PLHIV, screening also reduces the risk of severe ‘unmasking’ of inflammatory
reconstitution inflammatory syndrome (IRIS) when starting ART,17,18 and may reduce early
mortality in the critical ill. TB screening serves to raise awareness of TB symptoms and can
have an important ‘indirect’ effect on subsequent health seeking, reducing subsequent
patient delays in health seeking as well as providing direct access to diagnosis. This is
especially pronounced in community-based interventions, and may have been a major
contributor to the success of two recent interventions that reduced undiagnosed infectious
TB at the population level.6,7 Finally, TB screening has clear opportunities for linkage with
HIV testing and care services, as discussed below.
Epidemiology of undiagnosed tuberculosis disease
The target of TB screening is undiagnosed infectious TB, which is still highly prevalent, as
summarised in Table 2.7,9,10,12,19–31 Variation between countries is marked and predates the
HIV epidemic.1,32,33 Lengthy delays in diagnosis and missed diagnosis are still reported by
many HIV-positive and HIV-negative TB patients, despite major investment in
strengthening health systems and TB services during the last decade.17,18,34,35
Patient delays in seeking care can also be prolonged, particularly among HIV-negative TB
patients, for whom recent estimates suggest a mean duration of smear positivity before
diagnosis of >1 year in Africa and even longer in many parts of Asia. In contrast, HIV-
related TB progresses more rapidly, with a relatively brief duration of infectiousness (mean
of a few weeks to months).20,25,26 A substantial percentage of the total burden of
undiagnosed smear-positive TB in the general community, the main driver of TB
transmission, is thus HIV-negative individuals, even in very high HIV prevalence settings
(Table 2 and Figure 336). HIV-related TB, however, dominates the epidemiology of
undiagnosed disease in facilities (Table 2).
Undiagnosed infectious TB in HIV-negative individuals is an important control target
because of its disproportionate contribution to community transmission, and also due to the
high responsiveness to interventions. For example, in Zimbabwe, the prevalence of culture-
positive TB fell by 61% in HIV-negative individuals but only 25% in HIV-positive
individuals (overall decline 41%) during a 2.5 year intervention based on 6-monthly periodic
TB screening in the community targeting individuals with chronic cough and using smear
microscopy for diagnosis.7 By the end of the intervention, most undiagnosed infectious TB
was HIV-related (Table 2: study 5), illustrating the need for combined approaches to prevent
prolonged transmission from HIV-negative patients and reducing the high incidence of new
TB disease among PLWHA.7
Whom to target?
Subgroups in whom undiagnosed TB prevalence is consistently ≥1% (number needed to
screen [NNTS] of <100 to detect one case of TB if using perfect screening tools), and people
being considered for isoniazid preventive therapy (IPT) are the natural focus of screening
efforts.16 These include patients attending HTC clinics or HIV care clinics,18,37–39 un-
selected medical admissions and out-patient attendees,9,38 household contacts of TB
patients,21,40 prisoners,38 silica-exposed mineworkers,10 unselected adults in some
communities,12,19,21–23,26 and adult residents volunteering symptoms of TB during surveys
or outreach TB screening. Prevalence in adults in the general community and other risk
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groups, including diabetics, is highly variable and needs local situational analysis to guide
planning.7,34,41–43
Household contacts, PLHIV and facility attendees stand out as having much higher
prevalence rates than other risk groups (Table 2 and 38), indicating an urgent need for
effective TB screening using accurate diagnostic tools to provide individual benefit.
However, undiagnosed TB in these subgroups is more of a symptom than the main
contributor to TB transmission in communities.35,44
OPTIMAL SCREENING STRATEGIES FOR DIFFERENT PRIORITY GROUPS
TB screening has a number of different goals and entry points (Figures 1 and 2) affecting
where, how and how often screening should be carried out. For instance, prevention of
mortality is the overriding goal when screening acutely ill in-patients, and ideally requires
diagnostics able to rapidly detect disseminated HIV-related TB (Figure 2). At the other
extreme, interventions aimed at reducing transmission in the general community need to
detect infectious participants affordably and efficiently (Figure 2). Critical decisions include
which algorithm to use, and whether or not to screen for subclinical TB. Following the
general principals of screening, sensitive screening tests should be confirmed by a highly
specific test.45 As no current TB screening algorithm is ideal, compromises have to be
made.46,47 In practice, TB screening usually starts with either symptoms or X-ray,48
although there is increasing use of Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) as
both initial and confirmatory test.9,49–51
The performance of all tests tends to be less good due to lower sensitivity when used for
screening than for patient-initiated diagnostic testing, as the spectrum of undiagnosed
disease detected is shifted towards earlier, paucibacillary cases (Figures 2 and 3): this
includes culture, smear microscopy and Xpert.30,41,49,50,52–54 There is considerable
incremental yield from combining different tests, or repeating the same test on different
specimens.30,53,55 All tests also have relatively low positive predictive value when used for
screening, due to the lower prevalence of true disease.
Symptom screening
TB symptoms are the most common first step in TB screening, and may currently be the
only feasible option in many settings. However, undiagnosed TB can occur without any
reported TB symptoms and, irrespective of HIV status, less than half of culture-positive
participants have the ‘hallmark’ symptom of prolonged cough.18 In a meta-analysis of data
from 8148 PLHIV screened using culture, prolonged cough was reported by 1530 (20.0%)
participants and identified 260 (52.5%) culture-positive participants, while one or more of
the four symptoms (cough, fever, night sweats or weight loss) was reported by 3563 (46.6%)
participants, including 418 (84.4%) with confirmed TB.18
Subclinical tuberculosis
Subclinical TB (culture-positive TB with none of the above four symptoms) is consistently
identified whenever screening is carried out. In very high transmission settings, including
household contacts and newly diagnosed patients attending HIV care clinics, numbers of
patients with subclinical culture-positive disease can exceed symptomatic cases, and reach
very high rates (up to 15%).18,31,50,56 However, the consequences of missing subclinical TB
disease need to be weighed against the expense and consequences of more systematic
screening of all suspects. For example, adding extra steps in an already tortuous patient
pathway could increase loss to care.
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Individual consequences of missing subclinical active TB include IRIS, which is rarely fatal,
although extremely unpleasant and disruptive to HIV care.57,58 Inappropriate isoniazid
monotherapy may even be lifesaving in HIV-positive patients with difficult-to-diagnose
TB,59 and there is no clear evidence of increasing drug resistance.60,61 The extent to which
subclinical TB contributes to overall TB transmission is unclear,36 and will depend on how
infectiousness relates to symptoms (Figure 3). Local TB epidemiology can be dominated by
stable, minimally symptomatic but highly infectious ‘super-spreaders’,62 but this does not
appear to be a common phenotype,26 and pronounced reductions in undiagnosed TB at the
population level can be achieved without systematic screening for subclinical TB.7,11,12
Radiological screening
Chest radiography (CXR) provides the opportunity for high-volume TB screening, and is
increasingly feasible due to digital technology. Computer-aided diagnostics,63 validated
reading and scoring systems,64 remote reading and lay readers65,66 are all under active
investigation. CXR is already part of the adult and paediatric TB diagnostic algorithms, and
combines high sensitivity with reasonably high specificity.65,67,68 Immediate decisions on
the need for confirmatory testing and follow-up can be made by trained readers,64,66 as
exemplified by outreach interventions among hard-to-reach risk groups in Europe.65,69 HIV
immunosuppression affects radiological manifestations of TB; low sensitivity has been
reported in clinic-based screening,30,70 but not in community-based studies.48 Two studies
from Botswana reported a low-to-modest yield and high incremental cost of adding CXR to
clinic-based symptom screening.71–73 The main barriers to use are the high capital costs,
radiation hazard and lack of skill base in Africa.
New tuberculosis diagnostics for tuberculosis screening
Xpert and urinary lipoarabamannan (LAM) antigen detection are both new diagnostics being
used for TB screening, mainly in the context of HIV care. The development and roll-out of
the Xpert platform is a major breakthrough for the diagnosis and management of HIV-
related TB and multidrug-resistant TB (MDR-TB) that was endorsed by the WHO in
2010.74 It has increased sensitivity compared to smear microscopy, and has led to a
clinically important decrease in time to diagnosis and treatment initiation in self-presenting
patients with suspected TB. The sensitivity of Xpert compared to culture is highest in
hospital in-patients with TB symptoms (82–91%).75
Data on the use of Xpert as a TB screening tool in high HIV prevalence populations are
currently limited to four studies (Table 3);9,49–51 however, these numbers are likely to
increase rapidly. Excluding one very small study of five culture-positive cases, the
sensitivity of Xpert compared to culture was lower when used for diagnostic testing (range
58.3–88.2%), but much more sensitive than smear microscopy (sensitivity range 17.6–
52.8%). Use of Xpert for routine diagnostic testing is likely to be cost-effective in many
settings;76,77 however, affordability, limited throughput capacity and substantially lower
sensitivity than culture and CXR may restrict the widespread adoption of this test for
screening to specified high TB prevalence groups, such as PLHIV, facility attendees and
close contacts, and to confirmatory testing after CXR or symptom screen. More research is
needed to define sensitivity, specificity and feasibility in these groups.
LAM is a Mycobacterium tuberculosis cell-wall polysaccharide that can be detected in the
urine of TB patients, and is now available as a point-of-care lateral flow assay.29 It is a
useful screening test in PLHIV with advanced immunosuppression, diagnosing disseminated
disease that tends to smear-negative. Its low sensitivity and suboptimal specificity limit the
value of the test in patients with CD4 count of >200 cells/mm.29 LAM has marked
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prognostic significance predictive of high mortality, and a number of clinical trials are
ongoing in South Africa and Uganda.
MANAGEMENT OF HIV AND TUBERCULOSIS IN SCREENING
PARTICIPANTS
Integrating TB screening with HIV testing and care
TB screening during HIV care (Figure 1) is a high priority from multiple different
perspectives, and the subject of recent comprehensive and systematic reviews.18,75
Screening newly diagnosed PLHIV targets a patient group with a high prevalence of
undiagnosed TB disease, indications for IPT, high vulnerability to rapidly progressive TB
with a fatal outcome and collective vulnerability to nosocomial transmission through a
shared respiratory contact network at the HIV care clinic. Intensive TB screening with Xpert
MTB/RIF and culture can increase pre-ART identification of TB patients
dramatically,30,31,39,50,78 leading to a low incidence of TB in the subsequent 12 months.
Tests with pronounced prognostic significance include detectable bacilli or antigen in urine
or blood which identify individuals with high risk of early death.39,55
How best to integrate HIV testing and care into TB screening interventions delivered outside
of HIV programmes is less well defined. At a minimum, it is essential to confirm positive
TB screening results and ensure that patients are promptly linked into TB care, with
diagnostic HIV testing offered to all TB patients and participants with TB symptoms. As
routine programmes lose about 15% of their newly diagnosed smear-positive TB patients
and over 70% of newly diagnosed HIV-positive patients before any treatment is provided,
care needs to be taken to avoid loss to follow-up between diagnosis and treatment. Loss to
follow-up can be much higher when the diagnosis is made outside the routine setting,
undermining the effectiveness of TB-HIV screening.41
ART is by far the most effective method of preventing HIV-related TB, with a 65%
reduction in incidence, rising to 84% if the CD4 count is <200 cells/mm.11,79 Irrespective of
their final diagnosis, people identified as having symptoms of TB have a high probability of
being HIV-infected,22,80 being unaware of their HIV status, being eligible for ART80 and
having a high risk of death if their HIV is not promptly diagnosed and treated.80–83 Indeed,
in settings with generalised HIV epidemics, the NNTS to identify one patient with
undiagnosed HIV is far lower than the NNTS to identify one patient with undiagnosed TB.
More completely integrated TB-HIV interventions include HIV treatment-as-prevention
(TasP) strategies providing home-based HTC with TB screening and immediate ART and
IPT for HIV-positive individuals,84 and combined TB and household-based HIV and TB
prevention.6 ART for TasP has extremely high potential as a TB control strategy, with
declining national and regional TB incidence apparent already just from routine ART scale-
up.84 Eight different trials of ART for HIV prevention that include TB outcomes are
currently underway or planned.85
Follow-up of suspected tuberculosis
Once TB is suspected, no diagnostic test is able to both rule-in and rule-out TB
accurately.30,86 As such, it is vital to ensure continuity of care by promptly diagnosing and
treating HIV infection, and by providing participants with follow-up management until TB
is confirmed or excluded.80 As symptoms develop within a short time in patients with
confirmed ‘sub-clinical’ TB, repeated assessment after a short interval can distinguish
progressive TB disease from false-positive screening results.56
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In Harare, Zimbabwe, only 20% of smear-negative ‘TB suspects’ identified in the
community attended free follow-up care services.87 Participants who attended follow-up had
a high prevalence of undiagnosed HIV infection, a high rate of smear-negative TB
diagnosis, and high mortality at 12 months during a period of very limited access to ART.80
TUBERCULOSIS SCREENING USING DIFFERENT TUBERCULOSIS ENTRY
POINTS
Community-based screening for tuberculosis regardless of symptoms (entry points 1 to 3)
Community-based TB screening has not been included in international recommendations for
TB control for several decades.88 Before the mid-1970s, radiological screening was widely
implemented, but without clear demonstration of its impact on TB epidemiology or
individual benefit.44,88 Mobile radiography is still used in some European towns to screen
high-risk groups such as the homeless and drug users, with acceptable NNTS and cost-
effectiveness.65,69
The South African mining industry has used annual screening since the 1930s. The onset of
the HIV epidemic was associated with decreasing proportions of TB in miners diagnosed
using annual CXR screening.67 TB found using screening had lower case fatality rates: an
individually randomised trial of 6-monthly vs. the standard of care 12-monthly CXR
screening of 2634 gold miners led to a 52% reduction in the risk of death during the first 2
months of anti-tuberculosis treatment in the more intensively screened arm.8 Radiography in
miners has much lower sensitivity for culture-confirmed TB (~25%) than screening-naïve
populations (>90%), potentially reflecting ‘screening escape’.89
CXR screening is highly efficient, and should be investigated in very high transmission
settings, for example, combined with other intensified TB-HIV activities in South African
townships where the adult prevalence of culture-positive TB is up to 4% (NNTS ~25), and
for outreach screening in prisons. Another obvious application would be in facility-based
screening (Figure 1).
Outreach tuberculosis screening in general communities (entry points 2 and 3)
Outreach interventions in general communities also show promise. Here the aim is to
provide access to diagnosis of symptomatic TB in the community. Studies in Zimbabwe and
South Africa have shown high uptake, with 2–5% smear positivity prevalence in
participants.7,41 Epidemiological impact was assessed in a cluster randomised trial, with 46
neighbourhoods in Harare, Zimbabwe (DETECTB) randomised to six rounds of 6-monthly
active case finding using door-to-door enquiry for chronic cough in the household or mobile
van with loudspeakers.7 Participants provided sputum for smear microscopy results. Smear-
positive TB case notification rates increased substantially in both arms, with the mobile van
arm diagnosing the most smear-positive TB. There was a substantial and highly significant
reduction in population-level culture-positive TB (before:after adjusted reduction of 41%
over 2.5 years, from 7.9 per 1000 adult residents). An estimated 15–25% of undiagnosed
smear-positive residents were diagnosed at each intervention round,7,21 despite the intrinsic
limitations of using a low sensitivity screening algorithm (chronic cough and microscopy7).
In contrast, a large cluster multifactorial randomised trial of 24 communities in Zambia and
South Africa provided with 3 years of 1) enhanced case finding (ECF) in the community,
and 2) household intervention,22,43 did not show any epidemiological benefit from the ECF
intervention despite considerable participation. DETECTB and ZAMSTAR (Zambia South
Africa TB and HIV Reduction) ECF were complex interventions with several differences:
there was less focus on direct sputum collection in ZAMSTARECF, and DETECTB
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included dedicated follow-up clinics for smear-negative patients and active tracing of smear-
positive patients.
TB REACH, a case-finding initiative funded by the Canadian International Development
Agency and coordinated by the WHO, is also providing numerous examples of highly
successful TB screening interventions,15,90–93 including a number of interventions using
Xpert supported by UNITAID. So far the emphasis has been on increasing case detection,
rather than follow-up, to show declining TB incidence trends.
Combined TB-HIV household contact tracing interventions (entry point 4)
Household contacts of TB patients are at high risk for undiagnosed TB,40,94 with two recent
meta-analyses reporting a median yield of undiagnosed TB of 3.1% and 4.5%.40,94
Pronounced heterogeneity by region and screening algorithms was noted, with one recent
study showing very high rates of subclinical culture-positive disease (Shapiro in Table 2).24
According to conventional wisdom, intensive household contact tracing has limited potential
to affect TB epidemiology, although of high individual benefit, as only about 10% of TB
patients report household TB exposure.35 However, this has been challenged by a recent
study (ZAMSTAR) that showed significant (22%) reduction in undiagnosed culture-positive
TB in the general community through a cluster randomised trial that combined TB
screening, HIV testing and prevention counselling in Zambia and South Africa
(‘ZAMSTAR’ Household Arm6). The intervention was intensive, with three separate visits
over the course of 12 months. Fitting of mathematical models to trial data suggests diffusion
of indirect benefits beyond households directly covered by the intervention.43 The major
challenge of timely contact screening is the need for efficient communications,
transportation and a means of interacting with the community.
Broader facility-based tuberculosis screening (entry point 5)
Relatively few studies have assessed systematic screening of general out-patient clinic or
primary care clinic attendees for TB in HIV-prevalent settings;9 however, there are many
reasons for prioritising intensified screening for this entry point: first, it is a natural
extension of TB screening provided in HIV care settings, as general clinic attendees have
high HIV prevalence and high rates of undiagnosed TB.9 Second, it is an opportunity to
strengthen provider-initiated HTC,95 and numerous studies have shown poor identification
and management of people with TB symptoms in routine systems. Finally, screening all
facility attendees for cough is already part of infection control policy.96 A recent
intervention in the low HIV prevalence country of Pakistan greatly increased case
notification rates using lay volunteers to provide out-patient screening, based around a
mobile phone system for communication and payment of incentives.97
Facility-based interventions have the potential for population-level impact if they are
implemented well enough. The first clear example of this was from Cape Town, South
Africa, where a substantial fall in undiagnosed TB was reported for a community served by
an unusually strong TB-HIV health clinic.12
COSTS, COST-EFFECTIVENESS AND MATHEMATICAL MODELLING OF
TUBERCULOSIS SCREENING INTERVENTIONS
An increasing number of studies are estimating full screening costs and the cost-
effectiveness of TB screening. Costs per participant found to have TB are higher for TB
screening than for patient-initiated diagnosis: for example, US$1117 per patient41 in a South
African community-based TB screening intervention and approximately US$809 under the
Corbett and MacPherson Page 8
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2014 March 26.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
various interventions funded through the TB REACH initiative.15 However, these estimates
do not include costs averted, for example, from managing patients found at an earlier stage
of disease, nor from episodes of disease and death averted. Costs incurred through false-
positive diagnoses also need to be included. Even relatively small per-patient costs will
require substantial additional funding to be affordable by national TB control programmes in
low-income countries.98 Effective targeting to high TB prevalence risk groups and
populations will be critical for maximising cost-effectiveness.44
KNOWLEDGE GAPS AND RESEARCH PRIORITIES IN TUBERCULOSIS
SCREENING
Major gaps in our knowledge remain. For community-based interventions, these gaps lie in
some critical areas.44 It is still unclear to what extent TB screening can contribute to reduced
TB transmission, and, if so, how intensively, how often and for how long TB screening
interventions have to be delivered before appreciable gains are seen.36,99,100 The nature and
impact of critical health system constraints is also poorly defined, as are individual risks and
benefits from TB s screening, both for PLHIV and for HIV-negative participants.
Addressing our current knowledge gaps requires operational and public health research with
appropriate impact evaluation,101–103 and linked mathematical and economic modelling.
Understanding the impact of screening on ‘patient-important outcomes’ such as survival and
well-being, and population-level epidemiological impact are critical in guiding choices and
investment.44,46,104 Mathematical modelling can identify and clarify important key
principles, identify misconceptions, constraints and theoretical limitations, as well as being a
tool to guide realistic study design, cost-effectiveness and provide fuller analysis and
projection of real-life data.36,84,99,100,105
Among our most pressing needs are new diagnostics: a highly sensitive, portable, low-cost,
point-of-care diagnostic able to ‘rule out’ TB effectively would revolutionise TB screening
at all levels of the health system and community and allow rapid scale-up of HIV testing.
Furthermore, tools to enable efficient population-level impact evaluation, such as robust and
low-cost tests for recent TB infection able to evaluate transmission rates in communities and
quantify facility-level infection control are desperately needed (Table
4).7,22,30,31,39,43,58,78,101,103,106
Without a TB equivalent for HIV-incidence assays, large cohorts, repeated cross-sectional
measurements or analysis of time trends in TB incidence are required to measure trends in
TB control (Table 4). These are not only expensive, but also often fail to deliver clear
answers due to the logistical difficulties of this kind of indirect evaluation. Demonstration
projects providing high-intensity, high-coverage combined TB-HIV screening interventions
could provide relatively rapid insight into which approaches to TB screening are most
effective in very high TB incidence settings. Both facility- and community-based
interventions need to be investigated for their acceptability and potential impact on the
population, including settings with high MDR-TB rates.84,107 Intervention design should
resist the temptation to over-emphasise sustainability and test low-intensity complex
interventions without first establishing effectiveness.
Without clear evidence to guide policy and practice, resources may be wasted on ineffective
interventions, and, conversely, the value of effective interventions may be grossly under-
estimated. The need to establish effectiveness is most pressing for community-wide
interventions, where costs and potential harms, but also potential benefits, are at their
highest, and where contemporary examples with impact evaluation have given conflicting
results.7,43
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Important operational questions include linkage and retention in TB-HIV care when
screening individuals not already in chronic care services. Health systems research priorities
include the feasibility of provider-initiated TB and HIV screening at the facility level, and
models of delivering interventions through community-directed approaches.96,108,109
CONCLUSIONS
In high HIV prevalence settings with high rates of morbidity and mortality from TB, the
evidence for pursuing much bolder TB screening policy and practice is compelling, despite
high cost and many remaining unknowns. Facility-based TB screening and screening of
household contacts should be greatly intensified, while developing evidence around
community-based interventions. As with HIV testing, a combination approach adapted to the
local epidemiology will be needed. Gains from each TB infection averted are unusually high
in the highly vulnerable HIV-infected members of the community, and the costs of TB
screening are small compared to expenditure on HIV care.
Effective intervention with the limited diagnostics available today will have to start without
clear evidence, but with investment in research to support impact evaluation, ideally at
individual, clinic, facility and population level. More innovative approaches to defining and
responding to needs include, for example, combined surveillance-response strategies used
for targeting efforts against other major infectious diseases.110 Geospatial and molecular
epidemiology could allow us to capitalise on existing epidemiological, demographic, health
service resource usage data.111
Combined TB and HIV interventions are essential if any gains made through TB screening
are to be maintained in high HIV prevalence settings, and they require joint planning,
implementation and financing from the early stages of planning. Effective linkage to
treatment and prevention of both TB and HIV needs to be the focus of special attention for
both TB and HIV screening. We cannot continue to tolerate high rates of undiagnosed TB in
communities and health facilities, but need to act in proportion to the threat to health and
wellbeing: the magnitude and consequences of XDR-TB and MDR-TB epidemics in South
Africa provide a graphic illustration of the huge cost of failure to implement effective TB
and HIV screening and care.
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Figure 1.
Patient flow and main entry points into TB screening. HIV entry points (5 and 6) are
considered separately from other targeted risk groups, such as household contacts (4). TB
screening can be directed against subclinical TB or at early stages of health seeking. TB =
tuberculosis; HIV = human immunodeficiency virus; HCW = health care worker.
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Figure 2.
TB progression along an individual patient pathway. Depending on the nature of TB
screening, individuals can be targeted at any point along their disease progression. This will
influence the choice of diagnostic tools and the principal aim of screening. TB =
tuberculosis; MDR-TB = multidrug-resistant TB; PLHIV = people living with HIV; NAAT
= nucleic acid amplification test; HIV = human immunodeficiency virus; ART =
antiretroviral therapy; IPT = isoniazid preventive therapy; CPT = cotrimoxazole preventive
therapy.
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Figure 3.
Possible patterns of disease progression and onset of infectiousness. TB screening gains in
terms of secondary infections averted and ease of diagnosis (sensitivity of diagnostic tools)
will depend on the pattern of onset of infectiousness relative to symptoms, and how the
screen is targeted. Screening may detect patients who are in the process of self cure
following transient culture positivity. Adapted from Dowdy et al.36 TB = tuberculosis.
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Table 1
Broad strategies and representative examples of different approaches to providing TB screening with
integrated HIV testing and care
Strategy TB-HIV integration Evidence of population-level
impact on epidemiology
1 Household TB
contact tracing
Visit and screen in households or
invitation for facility-based screening
Provide early TB detection and TB
preventive therapy following close
contact
Combine with HTC; ideally include
home-based initiation of TB and HIV
care
ZAMSTAR
Reduced prevalence of TB from
combined TB and HIV
intervention (Ayles)6
Requires rapid response
2 Screening and
testing for TB in the
general community
Outreach mobile services
Door-to-door visits
Community health worker visits:
• As part of annual
preventive screen
• As part of multi-disease
campaigns
Increase completeness of case detection
and reduced delay in TB diagnosis
Provide HIV testing: to all diagnosed
with TB, with symptoms of TB, or as
fully integrated TB-HIV screening
Ideally include home-based initiation of
TB and HIV care and prevention
DETECTB (increased case
notifications and reduced
undiagnosed TB; Corbett)7
Reduced mortality from increased
frequency of X-ray screening
(Churchyard)8
3 Testing for HIV in
the community,
combined with TB
screening
As for TB screening above Provide TB screening during HTC
Ideally initiate HIV and TB care and
prevention
Home-based HIV testing reaches
high coverage
Few examples of fully integrated
HIV and TB testing, and none
assessed from TB control
perspective
4 Facilitating access
to TB diagnostic
services
Sputum collection point
Preparation and transportation of
slides by CHWs
Avoid need to visit health facility for
initial TB diagnosis
One important negative result
(Ayles)6
ZAMSTAR: increased case
notifications in remote areas with
poor access to health facilities
5 Raising awareness
and community
mobilisation
Advertising and media campaigns
Engagement through existing
community-based organisations
Reduce patient delays in health seeking
Increase demand for services
One important negative result
(Ayles)6
6 Facility-based
screening for HIV
and TB
Provider-initiated screening at every
patient visit
Existing policy but poorly implemented O’Grady showed 23% of
unselected adult facility attendees
had culture-positive TB9
7 Strengthen general
facility-based
services
Courteous services
Efficient routine TB-HIV services
Use of sensitive TB diagnostics
High linkage and retention in care
Infection control
Existing policy but poorly implemented Churchyard showed no population
impact from community-wide
isoniazid without HTC despite
individual benefit10
8 Strengthen HIV
care services
Increase coverage of ART
Early detection of HIV and treatment
Increased use of isoniazid preventive
therapy
Highly successful scale-up of HIV care
services across Africa coinciding with
declining TB incidence rates
Strong evidence of impact on
individual, community and
regional TB incidence from ART
scale-up (Suthar)11
Middelkoop showed evidence of
community effect on undiagnosed
TB12
TB = tuberculosis; HIV = human immunodeficiency virus; HTC = HIV testing and counseling; ZAMSTAR = Zambia South Africa TB and HIV
Reduction; CHW = community health worker; ART = antiretroviral therapy.
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Table 3
Use of Xpert® MTB/RIF for screening
HIV prevalence
Culture-positive
n
Sensitivity of smear
microscopy
% (95%CI)
Sensitivity of
Xpert® MTB/
RIF
% (95%CI)Study Country Screening population % positive n
Lawn, 201252 South Africa ART clinic 100 515 81 22.2 (13.3–33.6) 58.3 (46.1–69.8)
O’Grady, 20129 Zambia
Medical admissions
able to produce
sputum
65 881 201 52.8 (45.1–60.4): HIV+48.6 (33.0–64.4): HIV−
88.2 (81.9–
92.6): HIV−
74.3 (56.4–
87.0): HIV−
Dorman, 201249 South Africa Prevalence survey ND 6893 187 17.6 (12.5–23.9): HIV+ 62.6 (55.2–69.5)
Ntinginya 201251 Tanzania Household contacts ND 219 5 60.0 (14.7–94.7): HIV− 100 (47.8–100)
HIV = human immunodeficiency virus; ART = antiretroviral therapy; ND = not done.
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2014 March 26.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Corbett and MacPherson Page 24
Table 4
Approaches to impact evaluation for TB screening interventions (adapted from102)
Impact being evaluated Study designs Expected outputs and examples
Any high-risk group
 Comparison of performance
characteristics between different
tests and algorithms
Cross-sectional studies evaluating new TB
diagnostics
Estimates sensitivity and specificity; can inform on
robustness of new diagnostic systems in resource-
poor settings30,31,78
Provides number-needed-to-screen per TB patient
diagnosed in different populations
HIV care clinics and household
contacts
 Direct cohort follow-up to
evaluate patient-important
outcomes following screening
Cohort studies comparing outcomes according
to whether or not/how screened
Appropriate comparator populations provided
by randomisation (e.g., step-wedge), or
historical or non-randomly selected
comparison cohorts
Outcomes post-screening can include numbers
diagnosed with TB at and after screen, vital status,
retention in care, time to TB treatment58
Cost effectiveness and consequences of false-
negative and false-positive screening results can also
be assessed
Well-defined high TB incidence
populations
 Time trends in TB case
notification rates compared to non-
intervention comparator populations
Time trend analysis for:
a. initial peak in case notifications
attributable to screening, and
‘additionality’ compared to
comparator and historic trends
b. post-peak accelerated rate of
decline in new cases
Need accurate routine case notification system; can
be confounded by other changes in routine TB
diagnosis/reporting
Requires disaggregation of routine case notification
data to subdistrict level (unless intervention is
district-wide)
 Time trends in deaths from
diagnosed/undiagnosed TB
Aiming for reduced diagnosed +/−
undiagnosed TB deaths ideally routine as well
as intervention participants
Need complete TB registration and outcome data for
diagnosed TB deaths Accurate capture of
undiagnosed TB deaths requires autopsy
 Prevalence surveys for
undiagnosed TB in the general
population
Repeated before-after, or cluster-randomised
cross-sectional outcomes
Requires very large sample sizes and consistent
survey methods
Change/difference in undiagnosed TB provides
outcome (less is always better). Several recent
examples7,22,39,43,107
Before:after change does not prove causality; aim for
major change in short time period to provide
strongest evidence104
TB transmission rates Before-after estimates, or cluster randomised
cohort or cross-sectional outcomes; requires
large sample sizes and consistent methods
Evidence of impact on TB transmission is an ideal
outcome, but difficult to measure and so not often
evaluated in high TB incidence settings; results
affected by HIV status
One recent example used an incidence cohort design
in schoolchildren22,43
TB prevalence in HIV-infected
patients
Assessed through repeated before-after design,
regular surveillance with time trends, or
cluster-randomised cross-sectional outcomes
New clinic attendees, or routine post-mortem
A key indicator of population-level TB control, and
also the main target of prevention for TB-HIV
interventions
Occurs at high prevalence and clearly linked to TB
transmission
TB = tuberculosis; HIV = human immunodeficiency virus
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